Cetera Investment Advisers
SUPN icon

Cetera Investment Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Cetera Investment Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
+5,715
New +$274K ﹤0.01% 4257
2026
Q1 		– Sell
-5,135
Closed -$255K – 4955
2025
Q4 		$255K Buy
+5,135
New +$250K ﹤0.01% 4041

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Cetera Investment Advisers's SUPN Position: Q2 2026 in Review

Cetera Investment Advisers opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 5,715 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #4257 among its holdings. This is a return to the name: Cetera Investment Advisers previously reported a position in SUPN as recently as Q4 2025.

Cetera Investment Advisers first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Cetera Investment Advisers held 5,715 shares of Supernus Pharmaceuticals worth $266K as of Q2 2026.
  • Supernus Pharmaceuticals was a new Cetera Investment Advisers position in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4257 holding.
  • Cetera Investment Advisers first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.